Sichuan Credit Pharmaceutical Co., Ltd.

This trial aims to study the pharmacokinetic characteristics of tizanidine hydrochloride oral solution (100 ml: 40 mg, calculated as C9H8ClN5S) developed and produced by Sichuan Creed Pharmaceutical Co., Ltd.; tizanidine hydrochloride produced by Covis Pharma Nidine tablets (Zanaflex®, 4 mg) are used as the reference preparation. The pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations are compared, and the differences in human pharmacokinetics of the two preparations are evaluated. The test preparation and the reference preparation are also evaluated. Safety of the formulation in healthy subjects.

Using pharmacokinetic parameters as endpoints, we compared oxcarbazepine oral suspension produced by Sichuan Creed Pharmaceutical Co., Ltd. and oxcarbazepine imported from Novartis Pharma Schweiz AG under fasting and high-fat postprandial administration conditions. To evaluate the differences in the degree and rate of absorption of oral suspension (trade name: Trileptal®/Trileptal®) in healthy adults, to evaluate the bioequivalence of the two preparations, and to evaluate the administration conditions of fasting and high-fat meals , the safety of oxcarbazepine oral suspension produced by Sichuan Creed Pharmaceutical Co., Ltd. in healthy adults.